In the interest of patient and product safety, the European Union is taking many actions against the introduction of counterfeit medicinal products onto the market. One of them is Directive 2011/62/EU of 8 June 2011. Its delegated acts are already in preparation, and soon all drug manufacturers will be required to use only packaging that allows for the complete verification of product authenticity. How to meet these requirements? Are GS1 standards sufficient to comply with EU requirements?
Anna Gawrońska-Błaszczyk, Institute of Logistics and Warehousing, Chief Specialist at the GS1 Poland Center: GS1 standards are a tool used to ensure the authenticity of medicinal products through the unique and global nature of markings in the form of agreed identification numbers and barcode symbologies. One of the requirements of the new EU directive will be to ensure such methods of identifying specific medicinal products that it will be possible to distinguish individual packages of these products from one another. GS1 standards provide this possibility, which was recognized by industry representatives several years ago and was reflected in the so-called European model for ensuring product authenticity. This model, which incorporates GS1 standards, was developed by the EFPIA association, which brings together representatives of the pharmaceutical industry at the EU level. Additionally, the effectiveness of this model was demonstrated as a result of a pilot implementation carried out several years ago in Sweden. Of course, a necessary condition for the implementation of the concept is the ability to share reliable product data by all participants in the supply chain. Therefore, it is essential to build a special database in which this data will be collected and then shared based on established rules. GS1 standards are already being used to confirm product authentication, for example in Turkey.
In Poland, the GTIN number is the primary identifier for medicinal products, and it is to be hoped that this situation will not change and that government agencies responsible for delegated acts will recommend these standards due to the benefits resulting from their use, such as more effective methods of withdrawing products from the market, an automated way of detecting products that have expired, a guarantee of product authenticity, or the reduction of medical errors during the administration of drugs in hospital units.








